"When Binh Nguyen, then a graduate student in biomedical engineering at the University of Toronto, was working in the renal engineering department of a local hospital, he was struck by what he felt was a suboptimal setup for dialysis treatment," writes Jordana Dixon in "Health startup helps patients become more independent," for the Globe and Mail on April 13, 2015.
eQOL Inc. is a University of Toronto and MaRS Innovation start-up company that participated in and graduated from the University of Toronto ...
MaRS Innovation enjoyed an exceptional year in 2014. Our team continues to collaborate with researchers within our membership to help bridge the commercialization gap between their world-leading research and creating successful start-up companies or licenses.
Here are our picks for the top 10 news stories from MaRS Innovation's portfolio.
1. Triphase Accelerator Corporation, in which MaRS Innovation is an investor, started the year with a bang by signing a collaboration and option agreement with Celgene Corporation. In October, Triphase initiated a Phase I clinical study ...
Vasomune Therapeutics, a MaRS Innovation start-up company from Sunnybrook Health Sciences Centre's Sunnybrook Research Institute, was featured in a BioCentury emerging company profile by Michael J. Haas.
The company is currently raising a Series A financing round and recently closed a seed investment with Genome Canada and an unnamed industry partner. MaRS Innovation also contributed a third of the investment, bringing the round's total to $1.5 million.
Haas' profile, "Vasomune: Lassoing Tie2," is available behind a paywall on the BioCentury website.
Here's a short ...
TORONTO (October 20, 2014) — Vasomune Therapeutics, a biotechnology start-up founded by Drs. Dan Dumont and Paul Van Slyke of Sunnybrook Research Institute (SRI) in partnership with MaRS Innovation, has received $1.5 million, in part through Genome Canada’s Genomic Applications Partnership Program (GAPP), to advance Vasculotide, the company’s lead Tie-2 activating agent, towards clinical development.
This announcement was covered in Biotechnology Focus.
The Honourable Ed Holder, Minister of State (Science and Technology) and Dr. Pierre Meulien, president and CEO of Genome Canada, announced ...